DaVita, Inc.(DVA) has witnessed strong momentum year to date, with its shares up 47.3% compared with the industry's growth of 14.8%. The S&P 500 composite has risen 19.5% in the same period. DaVita, carrying a Zacks Rank #2 (Buy) at present, is witnessing an upward trend in its stock price, prompted by the company's business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further. DaVita is a leading provider of dialysis ...

TAMPA, Oct. 8, 2024 /PRNewswire/ -- DaVita Kidney Care, a leading provider of kidney care services, has activated its emergency response plan in preparation for Hurricane Milton's landfall in Florida. DaVita's emergency response plans focus on proactively dialyzing thousands of patients ahead of the storm in more than 150 centers. "Dialysis is a life-sustaining treatment, and our patients face unique challenges during weather emergencies like Hurricane Milton," said Priya Sequeira, senior vice president at ...

DaVita Inc. (DVA) has been gaining from its business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further. However, concerns regarding its dependence on commercial payers and macroeconomic challenges persist. So far this year, this Zacks Rank #2 (Buy) stock has gained 50.3% compared with the industry's 14.8% growth and the S&P 500's 19.5% increase. The renowned global comprehensive kidney care provider has a market cap ...

Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived to be winners. However, stocks touching a new 52-week high are often predisposed to profit-taking, resulting in pullbacks and trend reversals. Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculations are not absolutely baseless, all stocks hitting a 52-week high are ...

Shares of DaVita (DVA) have risen 17.1% in the past three months, outperforming the Zacks Medical - Outpatient and Home Healthcare industry's growth of 13.5% and the broader Zacks Medical sector's return of 2.5%. DVA stock has risen 54.8% year to date, primarily due to rising demand for its dialysis services. The uptrend is likely to continue for the rest of 2024 and beyond as there should be a rising demand for dialysis services due to an expanding patient pool with end-stage renal diseases. Per a report, ...

DaVita HealthCare (DVA) closed at $163.16 in the latest trading session, marking a -0.65% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.29%. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq decreased by 0.31%. Coming into today, shares of the kidney dialysis provider had gained 11.27% in the past month. In that same time, the Medical sector gained 1.59%, while the S&P 500 gained 1.57%. The upcoming earnings release of DaVita ...

In the latest trading session, DaVita HealthCare (DVA) closed at $164.22, marking a -0.59% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.03%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.2%. Heading into today, shares of the kidney dialysis provider had gained 8.56% over the past month, outpacing the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54% in that time. Analysts and investors alike ...

Kidney care leader provides free health screenings and resources to create awareness around kidney disease and open discussion around health care access DENVER, Sept. 17, 2024 /PRNewswire/ -- DaVita (NYSE: DVA), a leading provider of kidney care services, today announced the launch of its 2024 nationwide community health tour beginning September 24. The DaVita Health Tour is a mobile health screening and chronic disease education program supporting local communities across the country. Now entering its thir ...

When stocks are cruising at or nearing all-time highs, it reflects considerable bullishness with trends where buyers are in control. Stocks making new highs tend to make even higher highs, particularly when analysts' positive earnings estimate revisions are rolling in. That's been precisely the case for Intuitive Surgical (ISRG) , SharkNinja (SN) , and DaVita (DVA) , all of which presently sport a favorable Zacks Rank and are trading near 52-week highs. Let's take a closer look at what's been driving the bu ...

Stock Performance - DaVita HealthCare shares have increased by 5 1% over the past month and hit a new 52-week high of $160 82 [1] - The stock has gained 50 5% since the start of the year compared to the 11 1% move for the Zacks Medical sector and the 17 5% return for the Zacks Medical - Outpatient and Home Healthcare industry [1] Earnings and Revenue - DaVita HealthCare reported EPS of $2 59 versus the consensus estimate of $2 47 in its last earnings report on August 6 2024 and beat the consensus revenue estimate by 0 74% [2] - For the current fiscal year the company is expected to post earnings of $9 99 per share on $12 8 billion in revenues representing a 17 95% change in EPS and a 5 43% change in revenues [3] - For the next fiscal year the company is expected to earn $11 42 per share on $13 31 billion in revenues representing year-over-year changes of 14 37% and 3 97% respectively [3] Valuation Metrics - DaVita HealthCare trades at 15 8X current fiscal year EPS estimates compared to the peer industry average of 24 1X [7] - The stock trades at 9 4X on a trailing cash flow basis versus its peer group's average of 14 2X and has a PEG ratio of 0 9 [7] Zacks Style Scores and Rank - DaVita HealthCare has a Value Score of A Growth Score of C and Momentum Score of D resulting in a VGM Score of B [6] - The company currently has a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates [8] Industry Comparison - The Pennant Group Inc (PNTG) a peer in the industry has a Zacks Rank of 2 (Buy) with a Value Score of C Growth Score of B and Momentum Score of B [9] - PNTG beat the consensus earnings estimate by 14 29% last quarter and is expected to post earnings of $0 92 per share on revenue of $677 7 million for the current fiscal year [10] - Shares of PNTG have gained 6% over the past month and trade at a forward P/E of 36 2X and a P/CF of 42 56X [11] - The Medical - Outpatient and Home Healthcare industry is in the top 18% of all industries indicating favorable conditions for both DVA and PNTG [11]